Relmada Therapeutics, Inc. (FRA:4E2)
Germany · Delayed Price · Currency is EUR | Market Cap | 615.26M +2,677.2% |
| Revenue (ttm) | n/a |
| Net Income | -51.06M |
| EPS | -0.95 |
| Shares Out | n/a |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | n/a |
| Open | 5.40 |
| Previous Close | 5.65 |
| Day's Range | 5.40 - 5.40 |
| 52-Week Range | 0.44 - 6.50 |
| Beta | n/a |
| Analysts | n/a |
| Price Target | n/a |
| Earnings Date | Aug 7, 2026 |
About Relmada Therapeutics
Relmada Therapeutics, Inc. operates as a clinical-stage biotechnology company in the United States. The company focuses on the development of NDV-01, a controlled-release intravesical formulation of gemcitabine and docetaxel, which is in Phase 2 clinical trial for patients with aggressive forms of non-muscle invasive bladder cancer; and Sepranolone, a neurosteroid epimer of allopregnanolone, which is Phase 2b-ready for the potential treatment of prader-willi syndrome, tourette syndrome, excessive tremor, and other diseases related to excessive ... [Read more]
News
Relmada Therapeutics initiated with a Buy at H.C. Wainwright
H.C. Wainwright initiated coverage of Relmada Therapeutics (RLMD) with a Buy rating and $12 price target The company’s NDV-01 is a “differentiated” sustained-release intravesical formulation for non-m...
Relmada Therapeutics Appoints CNS Drug Development Veteran Michael Quirk as Senior Advisor for Sepranolone Program
CORAL GABLES, Fla., June 11, 2026 (GLOBE NEWSWIRE) -- Relmada Therapeutics, Inc. (Nasdaq: RLMD, “Relmada” or the “Company”), a clinical-stage biotechnology company advancing innovative therapies for o...
Relmada Therapeutics Slides: Corporate presentation
Relmada Therapeutics has posted slides in relation to its latest quarterly earnings report, which was published on June 9, 2026.
Relmada Therapeutics Transcript: Jefferies Global Healthcare Conference 2026
NDV-01, an extended-release gemcitabine/docetaxel, showed strong phase II results and is advancing to phase III in both high-risk and intermediate-risk bladder cancer. A pre-filled syringe formulation aims to expand use beyond academia, with robust IP and financial runway through 2029.
Relmada Therapeutics to Present at the Jefferies Global Healthcare Conference
CORAL GABLES, Fla., May 28, 2026 (GLOBE NEWSWIRE) -- Relmada Therapeutics, Inc. (Nasdaq: RLMD, “Relmada” or the “Company”), a clinical-stage biotechnology company advancing innovative therapies for on...
Relmada Therapeutics Transcript: AGM 2026
The meeting saw approval of all proposals, including director elections and amendments to the equity plan and articles. Strategic acquisitions and disciplined management led to a sharp rise in share price and market capitalization, positioning the company for future growth.
Relmada Therapeutics files automatic mixed securities shelf
16:54 EDT Relmada Therapeutics (RLMD) files automatic mixed securities shelf
Relmada Therapeutics Earnings Call Transcript: Q1 2026
Robust 12-month phase II data for NDV-01 in NMIBC, strong cash position after $160M financing, and phase III RESCUE program set to launch mid-2026. Patent filings may extend exclusivity to 2047, and cash runway is projected through 2029.
Relmada Therapeutics Quarterly report: Q1 2026
Relmada Therapeutics has published its Q1 2026 quarterly earnings report on May 12, 2026.
Relmada Therapeutics Earnings release: Q1 2026
Relmada Therapeutics released its Q1 2026 earnings on May 12, 2026, summarizing the period's financial results.
Relmada Therapeutics Reports First Quarter 2026 Financial Results and Provides Business Update
Positive 12-Month Phase 2 data for NDV-01 demonstrated a 95% complete response (CR) rate at any time and a durable 76% CR rate at 12 months in high-risk non-muscle invasive bladder cancer (NMIBC), and...
Relmada Therapeutics Slides: Company presentation
Relmada Therapeutics has posted slides in relation to its latest quarterly earnings report, which was published on May 12, 2026.
Relmada Therapeutics Slides: Corporate presentation
Relmada Therapeutics has posted slides in relation to its latest quarterly earnings report, which was published on May 12, 2026.
Relmada Therapeutics to Report First Quarter 2026 Financial Results on Tuesday, May 12, 2026
CORAL GABLES, Fla., May 06, 2026 (GLOBE NEWSWIRE) -- Relmada Therapeutics, Inc. (Nasdaq: RLMD, “Relmada” or the “Company”), a clinical-stage biotechnology company advancing innovative therapies for on...
Relmada Therapeutics to Present NDV-01 Abstracts at AUA2026
CORAL GABLES, Fla., May 05, 2026 (GLOBE NEWSWIRE) -- Relmada Therapeutics, Inc. (Nasdaq: RLMD, “Relmada” or the “Company”), a clinical-stage biotechnology company advancing innovative therapies for on...
Relmada Therapeutics Proxy statement: Proxy filing
Relmada Therapeutics filed a proxy statement on April 17, 2026, providing details for shareholder voting and corporate governance matters.
Relmada Therapeutics Proxy statement: Proxy filing
Relmada Therapeutics filed a proxy statement on April 17, 2026, providing details for shareholder voting and corporate governance matters.
Relmada Therapeutics Proxy statement: Proxy filing
Relmada Therapeutics filed a proxy statement on April 6, 2026, providing details for shareholder voting and corporate governance matters.
Relmada Therapeutics Registration statement: Registration filing
Relmada Therapeutics filed a registration statement on April 3, 2026, providing details about a securities offering with the SEC.
Relmada Therapeutics Slides: Corporate presentation
Relmada Therapeutics has posted slides in relation to its latest quarterly earnings report, which was published on March 30, 2026.
Relmada Therapeutics initiated with an Overweight at Piper Sandler
Piper Sandler initiated coverage of Relmada Therapeutics (RLMD) with an Overweight rating and $12 price target The firm says the company is advancing NDV-01, a novel intravesicle treatment for non-mus...
Relmada Therapeutics price target raised to $19 from $10 at Mizuho
Mizuho analyst Uy Ear raised the firm’s price target on Relmada Therapeutics (RLMD) to $19 from $10 and keeps an Outperform rating on the shares. The company reported “productive” Q4…
Relmada Therapeutics Earnings Call Transcript: Q4 2025
2025 saw major clinical and financial milestones, including strong NDV-01 phase II data, FDA alignment for phase III, and a $160M financing extending runway through 2029. NDV-01's efficacy and safety profile position it as a potential best-in-class NMIBC therapy.
Relmada Therapeutics Annual report: Q4 2025
Relmada Therapeutics has published its Q4 2025 annual report on March 19, 2026.
Relmada Therapeutics Earnings release: Q4 2025
Relmada Therapeutics released its Q4 2025 earnings on March 19, 2026, summarizing the period's financial results.